Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.
Original title: “Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute”
celiac disease emerging after asct in multiple myeloma a rare diagnostic intersection and literature review
Original title: “Celiac Disease Emerging After ASCT in Multiple Myeloma: A Rare Diagnostic Intersection and Literature Review.”
pancytopenia as the initial presentation of celiac disease
Original title: “Pancytopenia as the Initial Presentation of Celiac Disease.”
fibrillar type dermatitis herpetiformis an underrecognized variant that is rarely associated with celiac disease and lacking epidermal transglutaminase deposition a report of two cases
Original title: “Fibrillar-Type Dermatitis Herpetiformis: An Underrecognized Variant That Is Rarely Associated With Celiac Disease and Lacking Epidermal Transglutaminase Deposition: A Report of Two Cases.”
The star of the takeover is Forte Biosciences' investigational antibody therapy, FB102, which has shown early potential in vitiligo and celiac disease.
Original title: “Argenx deepens immuno expertise with $2.2B Forte Biosciences buy”
severe anemia in a child with newly diagnosed celiac disease and suspected parvovirus b19 associated erythroid suppression
Original title: “Severe Anemia in a Child With Newly Diagnosed Celiac Disease and Suspected Parvovirus B19-Associated Erythroid Suppression.”
For the ~1 in 100 people living with celiac, the burden of disease extends far beyond their plate.
Original title: “Celiac disease is entering a new era of therapeutic innovation”
cavitating mesenteric lymph node syndrome a rare complication of celiac disease case report and literature review
Original title: “Cavitating mesenteric lymph node syndrome: a rare complication of celiac disease-case report and literature review.”
The Food and Drug Administration (FDA or we) is extending the comment period for the notice that appeared in the Federal Register on January 22, 2026. In the notice, FDA requested data and information on the issues raised in and specific questions related to a citizen petition from Celiac Journey related to labeling and preventing cross- contact of gluten for packaged foods. We are taking this action in response to a request for an extension to allow interested persons additional time to submit
Original title: “Labeling and Preventing Cross-Contact of Gluten for Packaged Foods; Request for Information; Extension of Comment Period”
The Food and Drug Administration (FDA or we) received a citizen petition from Celiac Journey requesting that we act to protect consumers with celiac disease by requiring that all ingredients with gluten be listed by name in the ingredient list and by requiring cross- contact controls with gluten-containing grains. We are issuing this document to request comment on the issues raised in the petition and on specific questions related to these issues.
Original title: “Labeling and Preventing Cross-Contact of Gluten for Packaged Foods; Request for Information”